COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Vesair Clinical Trial (VAPOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04026347
Recruitment Status : Recruiting
First Posted : July 19, 2019
Last Update Posted : June 1, 2020
Information provided by (Responsible Party):
Solace Therapeutics, Inc.

Brief Summary:
Single-blind, multicenter, randomized clinical trial of the Vesair Balloon in the treatment of Stress Urinary Incontinence in post-menopausal women

Condition or disease Intervention/treatment Phase
Stress Urinary Incontinence Device: Vesair Balloon Other: Sham balloon placement Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Subject and assessor blinded to randomization result
Primary Purpose: Treatment
Official Title: An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Actual Study Start Date : February 1, 2020
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Vesair
Subjects are treated with Vesair Balloon at enrollment (day 0)
Device: Vesair Balloon
Indwelling, intravesical balloon

Sham Comparator: Sham
Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
Device: Vesair Balloon
Indwelling, intravesical balloon

Other: Sham balloon placement
Sham balloon placement procedure

Primary Outcome Measures :
  1. Composite Endpoint [ Time Frame: 6 months ]
    Pad weight + I-QOL

Secondary Outcome Measures :
  1. Pad Weight [ Time Frame: 6 months ]
    Reduction in pad weight

  2. I-QOL [ Time Frame: 6 months ]
    Improvement in I-QOL score (0-100 point scale, 100 being the best outcome)

  3. Episode Frequency [ Time Frame: 6 months ]
    Reduction in episode frequency as reported on a 7 day diary

  4. Patient Global Impression of Improvement (PGI-I) [ Time Frame: 6 months ]
    Significant Improvement per PGI-I (response of very much better or much better on 7 point scale)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-menopausal women with SUI for at least 12 months
  • Average of at least one leak per day
  • Failed non-invasive treatment
  • Willing to undergo cystoscopy and a minimum of 5 visits over one year

Exclusion Criteria:

  • BMI > 40.0
  • Last menstrual period within 12 months of enrollment
  • On birth control and/or oral hormone replacement therapy
  • Urge-predominant mixed incontinence
  • SUI due to intrinsic sphincter deficiency
  • Prior treatment with the Vesair Balloon
  • Prior medical, surgical or non-surgical treatment for SUI within 6 months of enrollment
  • Recurrent or recent (within the past 5 years) kidney stones
  • Recurrent or recent (within the past 3 months) Urinary Tract Infection
  • Stage 3 or higher cystocele (POP-Q)
  • Interstitial or follicular cystitis / painful bladder syndrome
  • Local genital infection
  • Artificial sphincter
  • Anatomic abnormalities which would interfere with device placement.
  • Visible blood in the urine
  • Uncontrolled bladder contractions / discomfort with bladder filling up to 300cc
  • History of cancer of the urinary tract
  • History of any cancer within the past two years (excluding non-melanoma skin cancers)
  • History of any cancer not (yet) treated with curable intent (excluding non-melanoma skin cancers)
  • Immunologically suppressed or immunocompromised
  • Undergoing pelvic radiation, pelvic fibrosis from previous pelvic radiation
  • Non ambulatory / unable to do simple pad weight testing exercises
  • On anticoagulation therapy with the exception of aspirin
  • History of mental illness requiring inpatient treatment
  • Neurological disease such as Parkinson's or multiple sclerosis
  • Uncontrolled diabetes (A1C > 9%)
  • Recent alcohol or drug abuse requiring treatment in the past year
  • Autoimmune or connective tissue disorders such as Marfan syndrome, Ehlers-Danlos or Myasthenia Gravis
  • Allergy to polyurethane or perfluorocarbons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04026347

Layout table for location contacts
Contact: Joshua A Freeman 508-283-1200 ext 168
Contact: Nicole Shugrue 508-283-1200 ext 165

Layout table for location information
United States, Arizona
Valley Urogynecology Associates Recruiting
Phoenix, Arizona, United States, 85016
Contact: Anna Downer    602-788-1521   
Principal Investigator: Shazia Malik, MD         
Sub-Investigator: Felipe Videla, MD         
Sub-Investigator: Paul Marshburn, MD         
Sub-Investigator: Daniel Stone, M.D.         
United States, California
Scripps Clinic Suspended
San Diego, California, United States, 92130
Tri Valley Urology Recruiting
Temecula, California, United States, 92592
Contact: Anita Deeds    951-698-1901 ext 232   
Principal Investigator: Benjamin T. Larson, M.D.         
United States, Connecticut
Women's Health Specialty Care Recruiting
Farmington, Connecticut, United States, 06032
Contact: Madeline Vazquez    860-678-7300 ext 5   
Principal Investigator: Jill Peters-Gee, M.D.         
Sub-Investigator: Adine Regan, M.D.         
United States, Florida
Florida Urology Partners Recruiting
Tampa, Florida, United States, 33615
Contact: Linda Seibert, M.S.    239-223-4488   
Principal Investigator: Osvaldo Padron, M.D.         
United States, Illinois
WomanCare Recruiting
Arlington Heights, Illinois, United States, 60004
Contact: Valerie Umbright    847-221-4241   
Principal Investigator: Randall Kahan, M.D.         
United States, Louisiana
Regional Urology Recruiting
Shreveport, Louisiana, United States, 71106
Contact: Leah Renfro    318-683-0411 ext 125   
Principal Investigator: Kevin Cline, M.D.         
Sub-Investigator: Allison Spann, M.D.         
Sub-Investigator: Ashley Baker, M.D.         
United States, Maryland
Chesapeake Urology Recruiting
Hanover, Maryland, United States, 21076
Contact: Wendy Paxton    443-471-5763   
Principal Investigator: Kaiser Robertson, M.D.         
Chesapeake Urology Suspended
Owings Mills, Maryland, United States, 21117
United States, Michigan
Mercy Health Not yet recruiting
Ada, Michigan, United States, 49301
Contact: Julie Bishop, RN    616-685-4691   
Principal Investigator: Jason Bennett, M.D.         
United States, Nevada
Freedman Urology Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Jose Medina    702-675-3102   
Principal Investigator: Sheldon Freedman, M.D.         
United States, New York
Premier Medical Group of the Hudson Valley Recruiting
Poughkeepsie, New York, United States, 12601
Contact: Lisa Gray    845-437-3804   
Principal Investigator: Daniel Katz, M.D.         
United States, North Carolina
Associated Urologists of North Carolina Recruiting
Raleigh, North Carolina, United States, 27612
Contact: Charlene Flahiff, MS    919-390-7352   
Contact: Glenna Gourley    919.390.7354   
Principal Investigator: Mark Jalkut, M.D.         
United States, Pennsylvania
Penn Medicine Recruiting
Philadelphia, Pennsylvania, United States, 19041
Contact: Zandra Kennedy    215-615-6569   
Principal Investigator: Lily Arya, M.D.         
Sub-Investigator: Uduak Andy, M.D.         
Sub-Investigator: Heidi Harvie, M.D.         
United States, Rhode Island
Women and Infants dept of Urogynecology Recruiting
Providence, Rhode Island, United States, 02903
Contact: Sara Veera, B.S.    401-274-1122 ext 48222   
Principal Investigator: Charles Rardin, M.D.         
United States, Virginia
Urology of Virginia Recruiting
Virginia Beach, Virginia, United States, 23462
Contact: Leigh Ann Brand    757-452-3421   
Principal Investigator: Kurt McCammon, M.D.         
Sub-Investigator: Jennifer Miles-Thomas, M.D.         
Sub-Investigator: Jessica DeLong, M.D.         
United States, Washington
Washington Urology Recruiting
Kirkland, Washington, United States, 98034
Contact: Kayla Lee, LPN    425-398-9355   
Principal Investigator: Karny Jacoby, M.D.         
Sponsors and Collaborators
Solace Therapeutics, Inc.
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Solace Therapeutics, Inc. Identifier: NCT04026347    
Other Study ID Numbers: CD1010
First Posted: July 19, 2019    Key Record Dates
Last Update Posted: June 1, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Solace Therapeutics, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Urinary Incontinence, Stress
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Behavioral Symptoms
Elimination Disorders
Mental Disorders